Linked Life Data

21327890

Source:http://linkedlifedata.com/resource/pubmed/id/21327890

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-3-14
pubmed:abstractText
In the last 30 years the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased substantially. This could be partly due to improvements in diagnostic imaging, which lead to the incidental diagnosis of asymptomatic cases. However, despite these improvements, patients typically experience long delays before they are diagnosed. In this review, we discuss both the limitations and advances in our understanding of the pathogenesis, molecular and cellular biology, diagnosis, classification, staging, and treatment of GEP-NETs in order to identify which factors could be contributing to the delay in diagnosis and timely treatment of these patients. Within this context, the results from the most relevant clinical trials the available targeted therapies for the treatment of GEP-NETs, such as the "RAD001 in Advanced Neuroendocrine Tumors," will be discussed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1573-7233
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
30 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
35-40
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Future perspectives on neuroendocrine tumors.
pubmed:affiliation
Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain. cdanicas@hotmail.com
pubmed:publicationType
Journal Article, Review